ARTICLE | Clinical News

Lucassin terlipressin: Phase III started

August 22, 2016 7:00 AM UTC

Mallinckrodt began the double-blind, placebo-controlled, North American Phase III CONFIRM trial to evaluate 1 mg IV Lucassin every 6 hours in about 300 patients. Lucassin is approved outside the U.S. and Canada to treat Type I HRS. ...